Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546398 | 1.00 | CTSA (0.49) | CTSAKMT2ASMN1; SMN2FFAR1RXRA | |
| SCHEMBL20545819 | 0.90 | CTSA (0.56) | CTSAKMT2ASMN1; SMN2RXRARXRB | |
| SCHEMBL20545820 | 0.90 | CTSA (0.56) | CTSAKMT2ASMN1; SMN2RXRARXRB | |
| SCHEMBL20546130 | 0.89 | KMT2A (0.58) | CTSAKMT2ASMN1; SMN2FFAR1RXRA | |
| SCHEMBL20546132 | 0.89 | KMT2A (0.58) | CTSAKMT2ASMN1; SMN2FFAR1RXRA | |
| SCHEMBL20545395 | 0.88 | CTSA (0.49) | CTSAKMT2ASMN1; SMN2FFAR1DHODH | |
| SCHEMBL20545398 | 0.88 | CTSA (0.49) | CTSAKMT2ASMN1; SMN2FFAR1DHODH | |
| SCHEMBL20545649 | 0.87 | KMT2A (0.48) | CTSAKMT2ASMN1; SMN2RXRARXRB | |
| SCHEMBL20545651 | 0.87 | KMT2A (0.48) | CTSAKMT2ASMN1; SMN2RXRARXRB | |
| SCHEMBL20545882 | 0.85 | CTSA (0.57) | CTSAKMT2ASMN1; SMN2FFAR1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885KMT2A 4455/4885SMN1; SMN2 2021/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885KMT2A 4455/4885SMN1; SMN2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.